- The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased by over 40% pre-market. This is why it happened.
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased by over 40% pre-market. Investors appear to be responding to a research report by Credit Suisse.
Credit Suisse had initiated coverage of Fulcrum Therapeutics with an “Outperform” rating and a $26 price target. The $26 price target imputes a 128.87% upside in the stock price as of the previous close.
Credit Suisse analyst Martin Auster noted he believes FTX-6058 for sickle cell disease offers a solid investment opportunity. And even though the program is just in a Phase 1 study in healthy volunteers, it should move into patients later this year.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
